Keep The Faith On This $4 Biopharma Stock
Tuesday, November 17, 2020 8:56 AM EDT
BDSI has seen explosive revenue growth its core flagship product BELBUCA since the end of 2017. Unfortunately, that huge sales ramp up has drawn little applause from Wall Street. This makes BDSI an incredibly cheap growth play.
In this article: BDSI